PRECLINICAL ASSETS MARKET ANALYSIS

Preclinical Assets Market, by Service ( Bioanalysis and DMPK studies (In vitro, In-vivo), Toxicology Testing (GLP, Non-GLP), compound management (Process R&D, Custom Synthesis, Asymmetric Synthesis & Others (Scale-up, cGMP, etc.), Safety Pharmacology, Others(Chemistry, etc.)), by Model type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model), by End user (Biopharmaceutical Companies, Government Institutes & Others (Academic and Research institutes) ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI5326
Pages :176
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

Lack of standardization as per international regulatory requirements

Global Preclinical Assets Market– Drivers

Increasing number of new test launch in the toxicology by the market players is expected to drive growth of the global preclinical assets market over the forecast period.

Increasing number of launch of new toxicology test by the key market players is expected to drive growth of the global preclinical assets market over the forecast period. For instance, in October 2018, SGS SA, a multinational company announced the launch of the in-vitro testing which consists of the development of present cell/tissue culture capabilities, flow cytometry, and mass spectrometry facilities, along with the introduction of high throughput screening, automation, and multiplexing technologies. The launch of this toxicology test will help the company to further strengthen and expand its product portfolio.

Increasing number of inorganic strategies such as acquisition by market players in North America is expected to drive growth of the global preclinical assets market over the forecast period.

Inorganic strategies such as acquisition by the key market players in North America are expected to drive growth of the global preclinical assets market over the forecast period. For instance, on May 9, 2022, Labcorp, a global life sciences company, and AtlantiCare, a health care organization in southern New Jersey, U.S., announced that they had closed a transaction to expand their long-term strategic relationship. Labcorp will acquire select assets from AtlantiCare’s clinical outreach business, which serves the AtlantiCare Physician Group and Affiliated Physicians and their patients across southern New Jersey, U.S. This collaboration will help the company in further expansion of laboratory services.